TSC1 and Facial Angiofibromas

Slides:



Advertisements
Similar presentations
Cancer: a genetic disease of inherited and somatic mutations n Gene mutations and/or genetic instability are involved in many cancers. n Viruses and environmental.
Advertisements

NF2/Merlin and Neurofibromatosis 2
What is Li-Fraumeni syndrome?
TSC2 and Tuberous Sclerosis Complex Disease Laura Koontz Biology 169.
Presented by: Jacqueline Holt March 4th 2003
Peutz-Jeghers Syndrome: LBK1/STK11 By Matt Wheeler.
NF2: A Tumor Suppressor NF2 encodes Merlin/Schwannomin, a protein that regulates cell growth and proliferation.
Fanconi Anemia & FANCD2
ZAFIA ANKLESARIA Role of BMPR1A in Juvenile Polyposis Syndrome Biology 169.
SMAD4/DPC4: A Tumor Suppressor James Brooks March 23 rd, 2006.
HCVM Member of  -herpesvirus family >200 ORFs Genes are expressed in a regulated cascade Some fulfill regulatory functions pUL38 expression during early.
Phosphatase and Tensin Homolog Deleted on Chromosome 10
NF2 = gene Merlin = protein…a.k.a. schwannomin Tumor Suppressor Tumor suppressive ability comes from partial inhibition of Ras/Rac signaling (phosphorylates.
MDM2: Oncogene Chan Lee. Discovery of MDM2: starting with tumor suppressor p53.
BRCA2 Blue: Rad51; Green: BRCA2
BRCA Genes Dallas Henson.
What is Cancer? How it occurs and cell cycle regulation.
Malignant Melanoma and CDKN2A
TSC and LAM: Current Treatment Options and Clinical Trials
WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5, (2004) 報告同學 : 陳宜芳 組 員 : 陳宜芳 陳彥任 葉儀君 莊健盈 王怡婷 黃冠誠 林佩儒 邱敏熙 楊瑞珠 楊玫琳 曾宜萱.
Tumor Suppressors Versus Oncogenes. The Cancer Phenotype is Usually Recessive R. Weinberg, Cancer Biology.
Molecular Biology of Cancer. CANCER TAKES TIME CANCER IS A DISEASE OF GENETIC MUTATIONS ACCUMULATION OF MANY MUTATIONS CAUSES CANCER.
BRCA1: Tumor Suppression and Breast Cancer A breast cancer cell dividing.
Problem 1 James is the only person in his kindred affected by DMD. He has one unaffected brother, Joe. DNA analysis show that James has a deletion in the.
NF2/Merlin: THE MAGIC OF MERLIN
Essentials of Biology Sylvia S. Mader
FGFR3 and Bladder Cancer Amy Fair March 29, 2005 Biol 169.
BMPR1A Bone Morphogenetic Protein Receptor 1 A (Juvenile Polyposis & Colon Cancer) Hallie Wieters.
TSC2 and Tuberous Sclerosis
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Copyright © 2002 Pearson Education, Inc., publishing as Benjamin Cummings Section D: The.
FANCD2 & the Fanconi Anemia Tumor Suppressor Pathway Shayna Purcell Joo et al., 333 (6040):
Cancer Accelerated Biology. Learning Objectives The different methods of diagnosing cancer. The difference between a malignant tumor and a benign tumor.
Tumor Suppressors Versus Oncogenes. Retinoblastoma is a Cancerous Disease Hereditary childhood cancer: bilateral tumors in 25-30% of cases unilateral.
TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.
PTEN (Cowden Syndrome) /.../ sld083.htm.
PTEN (Phosphatase and Tensin Homolog) a.k.a. MMAC1, TEP1 Raymond Stadiem.
Merlin, tumor suppressor 박건수 Cancer Genetics.
Genetics in TSC and LAM April 16 th 2016 Kevin C. Ess, MD, PhD Chief, Pediatric Neurology Depts. of Pediatrics and Neurology Vanderbilt University Medical.
Tuberous Sclerosis Abdullah M. Al-Olayan MBBS, SBP, ABP
Cowden’s Disease and PTEN. Cowden’s Disease (CD)  A rare autosomal dominant disease similar to Lehrmitte-Duclos Disease (LDD) and Bannayan-Zonana Syndrome.
HCDC4 & Endometrial Carcinoma Diana Rhyne. hCDC4 – Gene Information  Homologs in S. cervisiae, Drosophilia, and C. elegans  Tumor Suppressor  Expressed.
TSC1 Tuberous Sclerosis 1
The Problem of Cancer. What are cancer cells ? Cancerous growth involves unrestrained proliferation (malignancy) and spread (metastasis). Caused by: mutations.
Kate Bradford BIOL 445 March 5, 2009
Peutz-Jeghers Syndrome and LKB1/STK11
TSC1/2 Complex and Tuberous Sclerosis
Neurofibromatosis Type I (NF1)
The Role of SMAD4 (DPC4) in Cancer
NF2/Merlin Michael Anderson.
Bone Morphogenetic Protein Receptor 1A (BMPR1A) and Juvenile Polyposis Syndrome Cara Davidson March 18, 2004.
Tuberous Sclerosis TSC2/ Tuberin Alison Chappell.
p57 & Beckwith-Weidemann Syndrome
TSC1 in Facial Angiofibromas
TSC2 GENE ENCODES FOR TUBERIN
PTEN (a.k.a. MMAC1 and TEP1) and Cowden’s Disease
Graduate School of Medical Science & Egineering
The Role of Patch in Basal Cell Carcinoma
Volume 23, Issue 3, Pages (March 2016)
BIOLOGY 12 Cancer.
PTEN Tumor Suppressor Extraordinaire
Figure 1 mTOR complex biology
PTEN Tumor Suppressor and Cancer
The pathway signalling starts with the binding of insulin or growth factors to insulin receptors. The pathway signalling starts with the binding of insulin.
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer  Vassiliki Papadimitrakopoulou,
BMP Receptor 1a and Juvenile Polyposis Syndrome
Nat. Rev. Nephrol. doi: /nrneph
Volume 10, Issue 1, Pages (July 2002)
Multifunctional Tumor Suppressor
Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD 
Tobias B. Huber, Gerd Walz, E Wolfgang Kuehn  Kidney International 
Presentation transcript:

TSC1 and Facial Angiofibromas Mathilde Sabourin Biology 169 March 30, 2006

Tuberous Sclerosis Complex (TSC) Autosomal dominant inheritance of germline mutation in TSC1 or TSC2 Affects 1 in 6,000 people 65% of cases caused by sporadic mutations Almost 100% penetrance Widespread development of hamartomas Clinical triad for diagnosis Other common symptoms Susceptibility of organs to benign, rare tumors: brain, skin, heart, lungs and kidneys. Hamartomas=tumor-like growths; rarely progress to malignancy Clinical triad=mental retardation, seizures (caused by brain lesions) and adenoma sebaceum (facial angiofibromas) Other symptoms=autism and ADHD Besides facial angiofibromas, all of these other symptoms are infantile manifestations. Pulmonary lymphangiomyomatosis (LAM) is seen only in female TSC patients: benign smooth muscle cell proliferation in the lungs; often results in lung collapse. The highest morbidity and mortality is caused by brain and renal lesions.

Facial Angiofibromas Major cutaneous disfigurement Used in clinical triad to diagnose TSC

The TSC1 Gene Found on human chromosome 9q34 Encodes for Hamartin Tumor suppressor gene with TSC2 Expressed in all cells and tissues, but especially skeletal muscle cells; during all cell cycle phases, including G0 Proteins from TSC1 and TSC2 form a complex to function as a tumor suppressor.

Hamartin 130kDa hydrophilic protein No homology to tuberin (TSC2) Important coiled-coil domain Co-localizes with tuberin in cytoplasm Regulates cell growth and proliferation Or homology to other vertebrate proteins. Coiled-coil domain has been shown to be the only domain necessary for binding to tuberin and for the protein function Hamartin phosphorylation by CDK1 decreases activity of the protein complex; phosphorylation by GSK3B increases the stability of the complex. Hamartin could be responsible for the proper localization of the complex; or it could be needed to activate tuberin’s GAP domain.

Pathway for Hamartin Acts in insulin pathway for cell growth regulation Hamartin/tuberin complex suppresses Rheb Rheb activates mTOR pathway mTOR is a serine/threonine kinase that increases growth and proliferation by phosphorylating p70S6K and 4E-BP1 p70S6K phosphorylates ribosomal protein S6, which leads to increased ribosome biogenesis 4E-BP1 binds eIF4E and inhibits 5’ cap-dependent mRNA translation; inactive when phosphorylated, so protein synthesis can occur Rheb needs to be GTP-bound in order to activate mTOR. Hamartin/tuberin complex is a Rheb GAP, so it makes Rheb be GDP-bound and inactive. Growth factors and insulin cause the inactivating phosphorylation of hamarin and tuberin by several kinases; this then allows synthesis of proteins and growth. AKT/PKB/PI3K phosphorylate tuberin and suppress its GAP activity; CDK1 phosphorylates hamartin.

Pathway recap Insulin PI3K TSC1/2 Rheb 4E-BP1 mTOR S6K Protein synthesis

Two-hit model Tumor suppressor gene LOH seen in tumor tissues Most cases (65%) are sporadic So they have to be hit twice in their lifetime

Mouse model TSC1-/- is lethal Many problems with development Development of renal and extra-renal tumors Homozygous mutant embryos dies between 10.5 and 11.5 days Null mutants were pale and edematous, had pericardial effusions, hypoplastic liver, enlarged heart. 10% of heterozygous males died before 18mths, whereas 45% of heterozygous females died early. Death was usually caused by excessive amounts of blood in the peritoneal cavity (as a result of vascular tumors in the liver). Figure: A) macroscopic view of heterozygous and homozygous embryos at day 12. See unclosed neural tube and exencephaly. B) Histology of head region. Homozygous enlarged to twice the size. Arrows point to the unclosed region of the neural fold. C) Immunostaining of neural tube D) Histological analysis of the heart. Murine Embryo Fibroblasts with null TSC1 mutation had slower growth rate, less F-actin and focal adhesion formation, constitutive phosphorylation of S6 and S6K

TSC1 and Cancer Common mutations Up-regulated mTOR pathway LAM and “benign metastasis” Drosophila gigas mutant cells All TSC1 mutations are nonsense or frameshift mutations resulting in protein truncation. Loss of TSC1 causes constitutive activation of mTOR pathway, which leads to increased protein synthesis and the formation of clones of cells. LAM: Astrinidis et. al suggest a “benign metastasis” model for LAM pathogenesis, where benign TSC1 or 2 mutated cells can metastasize to the lungs from other organs; same TSC2 mutation was found in native LAM and recurrent LAM after lung transplant. This could be explained by the fact that cells without hamartin or tuberin can migrate aberrantly. They activate the GTPases that regulate the actin cytoskeleton, cell morphology and migration. Mutant in Drosophila homolog of TSC1; B shows enlarged eye size of mutant fly; C shows section of fly retina, with enlarged cells lacking rhabdomeres; D shows enlarged bristles on the anterior wing margin

Treatments Surgical removal of benign tumors CO2 laserbrasion for disfiguring facial angiofibromas Lung transplant for LAM Rapamycin reduces tumor size Rapamycin works downstream of TSC1/2 complex and inhibits mTOR. This has been shown to reduce the tumor size in mutants; it’s in clinical trials for treatment of LAM.

References Astrinidis A et. al. “Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.” Oncogene. 2005; 24; 7475-7481. Garami A et. al. “Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2.” Molecular Cell. June 2003; 11; 1457-1466. Kobayashi T et. al. “A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice.” PNAS. 17 July 2001; 98; 8762-8767. Kwiatkowski DJ et. al. “A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.” Human Molecular Genetics. 2002; 11; 525-534. Lamb RF et. al. “The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.” Nature Cell Biology. May 2000; 2; 281-287 Milolosa A et. al. “The TSC1 gene product, hamartin, negatively regulates cell proliferation.” Human Molecular Genetics. 2000; 9; 1721-1727. Tapon N et. al. “The Drosophila Tuberous Sclerosis Complex Gene Homologs Restrict Cell Growth and Cell Proliferation.” Cell. May 4, 2001; 105; 345-355. Van Slegtenhorst M et. al. “Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34.” Science. 8 August 1997; 277; 805-808. Van Slegtenhorst M et. al. “Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.” Human Molecular Genetics. 1998; 7; 1053-1057. http://www.dermatlas.org/derm/result.cfm?Diagnosis=186 http://www.csl.sony.co.jp/person/tetsuya/Pathway/Cancer-related/TSC/TSC1&2_1.0.html